Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "In vivo" evidence from FAP mice models

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Ferreira, Nelson ^a,b   Saraiva, Maria João ^a,b   Almeida, Maria Rosário ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

EPIGALLOCATECHIN GALLATE; GELATINASE B; HEAT SHOCK PROTEIN; MUTANT PROTEIN; PREALBUMIN; SERUM AMYLOID P; AMYLOID; BIOLOGICAL MARKER; CATECHIN; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; ENDOPLASMIC RETICULUM; FAMILIAL AMYLOID POLYNEUROPATHY; GASTROINTESTINAL TRACT; IN VIVO STUDY; LONG TERM CARE; MOUSE; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION; ANIMAL; COLON; DISEASE MODEL; DRUG EFFECT; ENDOPLASMIC RETICULUM STRESS; HUMAN; METABOLISM; PATHOLOGY; STOMACH; TRANSGENIC MOUSE;

ANIMALIA; MUS;

AMYLOID; AMYLOID NEUROPATHIES, FAMILIAL; ANIMALS; BIOLOGICAL MARKERS; CATECHIN; COLON; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM STRESS; HUMANS; MICE; MICE, TRANSGENIC; PERIPHERAL NERVOUS SYSTEM; PREALBUMIN; STOMACH;

EID: 84855650426     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029933     Document Type: Article

References (41)

1. Saraiva MJ, Birken S, Costa PP, Goodman DS, (1984) Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest 74: 104-119.
2. Benson MD, Kincaid JC, (2007) The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36 (4): 411-23.
3. Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RM, (2001) Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem 276 (29): 27207-13.
4. Cardoso I, Goldsbury CS, Müller SA, Olivieri V, Wirtz S, et al. (2002) Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils. J Mol Biol 317 (5): 683-95.
5. Sousa MM, Cardoso I, Fernandes R, Guimaraes A, Saraiva MJ, (2001) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 159: 1993-2000.
6. Ando Y, (2005) Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP). Med Mol Morphol 38 (3): 142-54.
7. Saraiva MJ, (2002) Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies. Expert Rev Mol Med 4 (12): 1-11.
8. Ferreira N, Cardoso I, Domingues MR, Vitorino R, Bastos M, et al. (2009) Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett 583 (22): 3569-76.
9. Ferreira N, Saraiva MJ, Almeida MR, (2011) Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Lett 585 (15): 2424-30.
10. Miyata M, Sato T, Kugimiya M, Sho M, Nakamura T, et al. (2010) The crystal structure of the green tea polyphenol (-)-epigallocatechin gallate-transthyretin complex reveals a novel binding site distinct from the thyroxine binding site. Biochemistry 49 (29): 6104-14.
11. Connelly S, Choi S, Johnson SM, Kelly JW, Wilson IA, (2010) Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol 20 (1): 54-62.
12. Kohno K, Palha JA, Miyakawa K, Saraiva MJ, Ito S, et al. (1997) Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am J Pathol 150: 1497-1508.
13. Santos SD, Fernandes R, Saraiva MJ, (2010) The heat shock response modulates transthyretin deposition in the peripheral and autonomic nervous systems. Neurobiol Aging 31 (2): 280-9.
14. Sousa MM, Fernandes R, Palha JA, Taboada A, Vieira P, et al. (2002) Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. Am J Pathol 161 (5): 1935-48.
15. Almeida MR, Macedo B, Cardoso I, Alves I, Valencia G, et al. (2004) Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem J 381 (Pt 2): 351-6.
16. Puchtler H, Sweat F, (1965) Congo Red as a stain for fluorescence microscopy of amyloid. J Histochem Cytochem 13 (8): 693-4.
17. Song EK, Hur H, Han MK, (2003) Epigallocatechin gallate prevents autoimmune diabetes induced by multiple low doses of streptozotocin in mice. Arch Pharm Res 26 (7): 559-63.
18. Isbrucker RA, Bausch J, Edwards JA, Wolz E, (2006) Safety studies on epigallocatechin gallate (EGCG) preparations. Part 1: genotoxicity. Food Chem Toxicol 44 (5): 626-35.
19. Teixeira PF, Cerca F, Santos SD, Saraiva MJ, (2006) Endoplasmic reticulum stress associated with extracellular aggregates. Evidence from transthyretin deposition in familial amyloid polyneuropathy. J Biol Chem 281 (31): 21998-2003.
20. Macedo B, Batista AR, do Amaral JB, Saraiva MJ, (2007) Biomarkers in the assessment of therapies for familial amyloidotic polyneuropathy. Mol Med 13 (11-12): 584-91.
21. Tennent GA, Lovat LB, Pepys MB, (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA 92 (10): 4299-303.
22. Sousa MM, do Amaral JB, Guimarães A, Saraiva MJ, (2005) Up-regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase-associated lipocalin, and matrix metalloproteinase-9 in familial amyloid polyneuropathy. FASEB J 19 (1): 124-6.
23. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, et al. (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15 (6): 558-66.
24. Suganuma M, Okabe S, Oniyama M, Tada Y, Ito H, et al. (1998) Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis 19 (10): 1771-6.
25. Lambert JD, Lee MJ, Lu H, Meng X, Hong JJ, et al. (2003) Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. J Nutr 133 (12): 4172-7.
26. Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, et al. (2010) EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci USA 27;107 (17): 7710-5.
27. Kim HS, Kim MH, Jeong M, Hwang YS, Lim SH, et al. (2004) EGCG blocks tumor promoter-induced MMP-9 expression via suppression of MAPK and AP-1 activation in human gastric AGS cells. Anticancer Res 24 (2B): 747-53.
28. Almeida MR, Gales L, Damas AM, Cardoso I, Saraiva MJ, (2005) Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses. Curr Drug Targets CNS Neurol Disord 4 (5): 587-96.
29. Altland K, Winter P, Saraiva MJ, Suhr O, (2004) Sulfite and base for the treatment of familial amyloidotic polyneuropathy: two additive approaches to stabilize the conformation of human amyloidogenic transthyretin. Neurogenetics 5 (1): 61-7.
30. Cardoso I, Saraiva MJ, (2006) Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J 20 (2): 234-9.
31. Macedo B, Batista AR, Ferreira N, Almeida MR, Saraiva MJ, (2008) Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochim Biophys Acta 1782 (9): 517-22.
32. Macedo B, Magalhães J, Batista AR, Saraiva MJ, (2010) Carvedilol treatment reduces transthyretin deposition in a familial amyloidotic polyneuropathy mouse model. Pharmacol Res 62 (6): 514-22.
33. Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ, (2010) Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med 8: 74.
34. Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, et al. (2003) Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 9 (9): 3312-3319.
35. Del Rio D, Calani L, Cordero C, Salvatore S, Pellegrini N, et al. (2010) Bioavailability and catabolism of green tea flavan-3-ols in humans. Nutrition 26 (11-12): 1110-6.
36. Hunstein W, (2007) Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option? Blood 110 (6): 2216.
37. Mereles D, Buss SJ, Hardt SE, Hunstein W, Katus HA, (2010) Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clin Res Cardiol 99 (8): 483-90.
38. Mereles D, Hunstein W, (2011) Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? Int J Mol Sci 12: 5592-5603.
39. Nakagawa K, Sheikh SI, Snuderl M, Frosch MP, Greenberg SM, (2008) A new Thr49Pro transthyretin gene mutation associated with leptomeningeal amyloidosis. J Neurol Sci 272: 186-190.
40. Nanjo F, Goto K, Seto R, Suzuki M, Sakai M, et al. (1996) Scavenging effects of tea catechins and their derivatives on 1, 1-diphenyl-2-picrylhydrazyl radical. Free Radic Biol Med 21: 895-902.
41. Guo Q, Zhao B, Li M, Shen S, Xin W, (1996) Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim Biophys Acta 1304: 210-222.